Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 9Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Aclarubicin × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡